Interleukin-17A (IL-17A)
Ultrasensitive Immunoassay
Rules-Based Medicine’s internally developed and manufactured ultrasensitive immunoassay to interleukin-17A (IL-17A) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of IL-17A in serum or plasma. The assay does not cross-react with IL-17F or IL-17C. The Simoa IL-17A assay is a pharmacodynamic analysis tool for autoimmune and chronic inflammatory diseases, and studies in oncology.
Interleukin 17A (IL-17, IL-17A, or CTLA8) is the founding member of the IL-17 family of cytokines, which contains six structurally similar proteins (IL-17A-F) that are derived from different cellular sources and play differing roles in inflammation. IL-17A is a proinflammatory cytokine and is a central player in immunity and host defense. Chronic activation of IL-17A is a critical driver for the immunopathogenesis of autoimmune diseases and is implicated in other chronic inflammatory conditions including some cancers. IL-17A is generated predominately by T helper 17 cells (Th17) but can also be produced by T CD8 cells, γδ T cells, NKT cells, mast cells, and neutrophils. Active IL-17A binds to the IL-17RA and IL-17RC receptor complex on non-hematopoietic cells, activating several signaling cascades to induce a variety of cytokines (IL-1β, IL-6, GM-CSF, and TNF) and chemokines promoting further activation and recruitment of immune cells.
Elevated levels of serum IL-17A have been observed in patients with rheumatoid arthritis, in the synovial fluid of patients with rheumatoid arthritis, and in the serum, synovial fluid, and psoriatic lesions of patients with psoriasis. Additionally, IL-17A is highly expressed in colorectal cancer patients and has been identified as a biomarker in combination with CCL20 to potentially diagnose and monitor disease progression. These shreds of evidence support the development of biologics targeting the IL-17A/IL-17R signaling axis for clinical use where the reduction of IL-17 has resulted in remarkable success in patients with these diseases.
Swiss-Prot Accession Number: Q16552
Alternate names for this biomarker include:
Cytotoxic T-lymphocyte-associated antigen 8, CTLA-8
| Biomarker | LLOQ* (Serum and Plasma) |
LLOQ* (Undiluted Samples) |
Volume Required | |
|---|---|---|---|---|
| Serum or plasma | Other fluids** | |||
| Interleukin-17A (IL-17A) | 0.048 pg/mL | 0.012 pg/mL | 100 µL | 150 µL |
* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.
** Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.